FREMONT, Calif. and APPENZELL STEINEGG, Switzerland, Aug. 6, 2025 /PRNewswire/ -- eJoule Inc has fulfilled a multi-ton bulk order of high performance doped and...
Company takes a major step to ensure a secure U.S. battery supply chain
CHESTER, S.C., Aug. 6, 2025 /PRNewswire/ -- Princeton NuEnergy Inc. (PNE), a U.S....
Q2 2025 Consolidated Highlights:
Consolidated revenues improved 5% from Q1 2025 to $957 millionOperating loss of $8.5 million and adjusted operating profit of $7.2 million...
"Market Analysis Highlights Growth Potential, Emerging Technologies, ESG Trends, and Strategic Insights in the Cell Line and Membrane Sector"
BOSTON, Aug. 5, 2025 /PRNewswire/ --...
SAN FRANCISCO, Aug. 5, 2025 /PRNewswire/ -- Posh Energy's fully owned subsidiary in Singapore, Posh Electric ("POSH"), has been awarded a grant from the...
A premium, clean protein powder engineered for fast recovery, lean muscle and maximum performance
High-res photography can be viewed here
LA CROSSE, Wis., Aug. 5, 2025...
Coordinated Project Plan (CPP) Brings All Participating Federal Agencies and the Company Together to Identify and Publicly Post All Project Reviews, Authorizations and Timelines...
Princeton NuEnergy (PNE), an innovator in lithium-ion battery recycling, wins a SuperBoost grant from the NSF Energy Storage Engine in Upstate New York.
VANCOUVER, British Columbia and BOSTON, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced equity inducement grants to six new non-officer employees consisting of an aggregate of 24,200 share options. All of the foregoing share options were approved by the Compensation Committee of the Company’s Board of Directors with an effective date of July 31, 2025 and were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
Presentation highlights Blacksmith's novel chemistry platform for targeting metalloenzymes and FG-2101, a first-in-class non-hydroxamate LpxC inhibitor
SAN DIEGO, Aug. 1, 2025 /PRNewswire/ -- Blacksmith Medicines,...
DELRAY BEACH, Fla., Aug. 1, 2025 /PRNewswire/ -- The report "Chromatography Resin Market by Type (Natural, Synthetic, Inorganic Media), Technique ((Ion Exchange (Cation and Anion), Affinity...